Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Angeles Alvarez Secord et al.|The Lancet Oncology|2019Cited by 533
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerGiorgio Bogani, Mansoor Raza Mirza, Bradley J. Monk et al.|Annals of Oncology|2024Cited by 123
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Kathleen N. Moore, Toon Van Gorp, Antoine Angelergues et al.|Journal of Clinical Oncology|2023Cited by 53
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.Nehal J. Lakhani, Kathleen N. Moore, Amita Patnaik et al.|Journal of Clinical Oncology|2020Cited by 37
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N. Moore, Johanna C. Bendell, David S. Hong et al.|Targeted Oncology|2021Cited by 25